Intelligence

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Metabolomics #Molecular medicine #Oncology #Pathology #Pharmacogenomics #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Applying the semantic web to drug discovery and development

Applying the semantic web to drug discovery and development By Dr Eric Neumann There is much happening in drug development these days: new target classes, increasing costs, new forms of high throughput screening, and the promise of personalised medicine. But of all the issues, the one that… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Oncology #PCR #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

High Content Screening – Emerging importance of novel reagents/probes and pathway analysis

High Content Screening – Emerging importance of novel reagents/probes and pathway analysis By Dr John Comley The number of high content screens will increase by 50% over the coming year; signal pathway analysis was seen as the most relevant high content screening (HCS) application; with greatest interest in… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Business #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomics #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Pharmokinetics #Screening #System biology #Systems biology #Target validation #Toxicology

Computer-aided design: progress towards more rational drug discovery

Computer-aided design: progress towards more rational drug discovery By Dr Wolfgang H.B. Sauer Drug discovery is a science, a craft and an art, and often it requires a fair amount of serendipity or plain luck to succeed. Success is rare and costly, as evidenced by numerous reports and… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Oncology #Pathology #Pharmacogenomics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

The Next Decade of Gene Expression Profiling

By Dr Y. Douglas Dolginow The art and science of prediction is a risky and humiliating exercise. As bad as we are at it, predicting things remains one of the fundamental human instincts, undoubtedly linked to a Darwinian selective advantage for our species. Read More

#Archive

#Academic #Analysis #Assay development optimisation & technology #Automation / robotics #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics

Ion Channels – New opportunities for an established therapeutic target class

Ion Channels – New opportunities for an established therapeutic target class By Dr Andrew Southan, Iain F. James and David Cronk There is an increasing recognition within the pharmaceutical industry of the immense potential for ion channels as a drug target class. Advances in the understanding of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biomarkers #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Immunology #Lead discovery #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Pharmokinetics #Regulatory #RNA #Screening #Stem cells #Therapeutics #Toxicology

Nanotechnology approaches to solving the problems of poorly water-soluble drugs

Nanotechnology approaches to solving the problems of poorly water-soluble drugs By Dr Roghieh Saffie-Siebert, Dr Jill Ogden and Dr Mark Parry-Billings Traditionally, almost half of new molecular entities identified by pharmaceutical industry screening programmes have failed to be developed because of poor water-solubility, which makes their formulation difficult… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Automation / robotics #Business #Cell culture #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Enabling technologies #High throughput screening #Immunology #Lead discovery #Lead optimisation #Molecular medicine #Preclinical #RNA #Screening #Stem cells

Creating a productive R&D culture

Creating a productive R&D culture By Janet White Increasing R&D productivity is the current mantra of pharmaceutical industry executives. The promise of new technologies and process improvements has been extensively discussed. However, fundamental culture change within research organisations remains the final unexplored frontier to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Lead discovery #PCR #Regulatory #RNA #Target validation

Ontologies – Semantic networks of pharmaceutical knowledge

Ontologies – Semantic networks of pharmaceutical knowledge By Dr Stephen P. Gardner In the current climate making information more transparent to internal R&D staff and to external audiences such as regulators and consumers is crucial to business effectiveness. A new generation of semantic technologies capable of generating a… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analytical chemistry #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #Lead discovery #Medicinal chemistry #Molecular medicine #Protein chemistry / Proteomics #Regulatory #RNA #Therapeutics

How a new compliance agenda is changing the face of the drug discovery industry

How a new compliance agenda is changing the face of the drug discovery industry By Dr Doug Dean and Frances Bruttin Safe and effective drug products for the 21st century can be developed if, and only if, firms understand the mechanism of action of their products, and they… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #Imaging #Immunology #Lead discovery #Organic chemistry #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Translational #Translational chemistry

Cryo Electron Microscopy and Electron Tomography

Cryo Electron Microscopy and Electron Tomography By Dr Jack Elands and Dr Ulf Skoglund Cryo electron microscopy and electron tomography will play a crucial role in the future of drug development. The completion of the human genome project has focused tremendous interest in determining… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Business #Cell therapy #Chemical engineering #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Lead optimisation #Pharmacology #Pharmokinetics #Preclinical #Regulatory #Screening #Toxicology

Exposure response modelling a safe and profitable way to speed drugs to market

Exposure response modelling a safe and profitable way to speed drugs to market By Dr Gregory Fisher and Dr Arthur L. Craigmill The applicability of physiologically-based pharmacokinetic modelling (PBPK) far exceeds that of classical PK in predictive pharmacokinetics, tissue dosimetry, drug efficacy, and drug safety. This in… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Imaging #In Silico Biology #Mass spectrometry / NMR #Metabolomics #Molecular medicine #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The search for validated biomarkers in the face of biosystems complexity

The search for validated biomarkers in the face of biosystems complexity By Professor Ian Humphery-Smith and Will Dracup As the pharmaceutical industry is all too well aware, the genomics and postgenomic sciences have delivered an excessive number of drug targets few of which have been well validated. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Lead discovery #RNA #Screening #Target validation

Compound Management – In pursuit of sample integrity

Compound Management – In pursuit of sample integrity By Dr John Comley In December 2004 HTStec published its report on Compound Management Trends. This market report summarises the results of a global benchmarking study on pharmaceutical compound management (CM), documenting current practices, issues and future trends in… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Cell culture #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Oncology #Pharmokinetics #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The Impact of RNAi on Drug Discovery

The Impact of RNAi on Drug Discovery By Dr Christopher P. Miller RNAi (RNA interference) is an important target validation tool that has risen to prominence since 2001. For a number of reasons, it has supplanted other pre-existing target validation tools and is now the method of choice… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Metabolomics #Microfluidics #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Overview of biomarkers in disease, drug discovery and development

Overview of biomarkers in disease, drug discovery and development By Professor Stephen Naylor The pharmaceutical industry and the healthcare sector are both confronted with expensive technological innovation, escalating costs and pointed questions about productivity and efficiency. The parallels between the problems of producing new therapeutic agents and… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Business #Chemistry #Clinical specialities #Drug development #Drug discovery #Genetics / genomics #Genomics #High Content Screening #Immunology #Molecular medicine #Oncology #Patent Law #RNA #Screening #Stem cells

Patent Pools as a Solution to the licensing problems of diagnostic genetics – United States and European perspectives

Patent Pools as a Solution to the licensing problems of diagnostic genetics – United States and European perspectives By Dr Jorge A. Goldstein, Dr Ted J. Ebersole, Marvin C. Guthrie, Annette A. Hirschfeld and Bart J. van den Broek Advances in diagnostic genetic testing have resulted in the… Read More

#Archive